Aspira Women's Health Reports Second Quarter 2022 Financial

Increased product revenue by 17% to $2.0 million; Grew OVA1plus volume by 19% to 5,411 units Entered into a research agreement with Harvard’s Dana Farber...

Related Keywords

United States ,Texas ,Nicole Sandford ,Ashleyr Robinson ,Aspira Geneti ,Office Of Aspira ,Lifesci Advisors ,Aspira Women Health ,Harvard Dana Farber Cancer Institute ,Aspira Women Health Inc ,Drug Administration ,University Of Lodz ,Nasdaq ,University Of Lodzfor ,Dana Farber Cancer Institute ,Bioreference Laboratories Inc ,Scarlet Health ,Medical University ,Second Quarter ,Chief Executive Office ,Operational Excellence ,Bioreference Laboratories ,Aspira Women ,Analytical Validation ,Deep Neural Network Algorithm ,Ovarian Cancer ,Cash Utilization ,Eastern Time ,Private Securities Litigation Reform Act ,Annual Report ,Relations Contact ,Sci Advisors ,Except Share ,Par Value Amounts ,Consolidated Statements ,Per Share Amounts ,Nasdaq Awh ,Spira Women 39s Health Inc ,